Biotechnology company Moderna said on Monday that it will be requesting emergency authorization for its coronavirus vaccine from the Food and Drug Administration.
A new analysis of Moderna's trials looked at 196 confirmed COVID-19 infections among 30,000 participants. Of those infections, 185 were in the placebo group, while just 11 were in the group that had been vaccinated, resulting in an efficacy rate of 94.1%.
The vaccine also appears to prevent those who have been infected from getting severely sick.
"This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease," Moderna CEO Stephane Bancel said in a statement. "We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death."
Moderna is the second drugmaker to file for emergency authorization, following Pfizer, which sought out the authorization on November 20.
The company will begin testing the vaccine on children between the ages of 11 and 17 later this year and on children under 11 next year. The emergency authorization will allow some adults to receive the vaccine.